Mizuno K, Niimura S, Tani M, Haga H, Gomibuchi T, Sanada H, Fukuchi S
Third Department of Internal Medicine, Fukushima Medical College, Japan.
Eur J Pharmacol. 1992 May 14;215(2-3):305-8. doi: 10.1016/0014-2999(92)90045-6.
MK 954 (DuP 753), a recently developed angiotensin II (Ang II) receptor antagonist, was administered orally for 2 weeks to spontaneously hypertensive (SHR) and Wistar-Kyoto rats (WKY). Whereas the basal levels of plasma Ang II were lower in SHR than in WKY, treatment with MK 954 markedly reduced blood pressure in SHR but not in WKY. Plasma renin activity, Ang I and Ang II were increased, while plasma aldosterone was decreased in both strains. These results no only indicate therapeutic efficacy of this agent in the chronic treatment of human hypertension, but also support the idea that the renin-angiotensin system plays an important role in the control of blood pressure in SHR.
MK 954（DuP 753）是一种最近研发的血管紧张素II（Ang II）受体拮抗剂，对自发性高血压大鼠（SHR）和Wistar - Kyoto大鼠（WKY）进行了为期2周的口服给药。虽然SHR的血浆Ang II基础水平低于WKY，但MK 954治疗显著降低了SHR的血压，而对WKY则无此作用。两种品系大鼠的血浆肾素活性、Ang I和Ang II均升高，而血浆醛固酮降低。这些结果不仅表明该药物在人类高血压的慢性治疗中具有治疗效果，还支持肾素 - 血管紧张素系统在SHR血压控制中起重要作用这一观点。
